Triumvira recently announced the clearance of it’s Investigational New Drug (IND) and Clinical Trial Applications (CTA) by U.S. and Canadian Health Authorities for its novel T cell therapy product TAC01-CD19 in patients with CD19-positive B-cell malignancies. The Phase 1/2 study (TACTIC-19, NCT03880279) is expected to be initiated in late 2019.
“Obtaining intellectual property protection of our TAC platform is a key milestone and confirms that TAC is a well-differentiated technology,” said Dr. Paul Lammers, Triumvira’s President and CEO. “Issuance of our composition of matter claims further strengthens our position as a company pioneering novel engineered T cell approaches as we are bringing this innovative treatment to patients.”